Navigation Links
Halozyme Reports Fourth Quarter and Year End 2012 Financial Results

SAN DIEGO, Feb. 25, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and year ended December 31, 2012.


"2012 was another productive year marked by key partner regulatory filings in Europe, as well as our establishment of a new collaboration with Pfizer," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "These advancements, coupled with the continued progress of our own pipeline products, leave Halozyme well-positioned for continued growth in 2013."

Fourth Quarter Highlights Highlights of Halozyme's fourth quarter and recent activities include:

  • Pfizer Collaboration: Entry into a worldwide Collaboration and License Agreement with Pfizer Inc. for the purpose of developing and commercializing products combining proprietary Pfizer biologics with Halozyme's Enhanze™ Technology.  Pfizer has elected three exclusive licenses to therapeutic targets in primary care and specialty care indications, and has the right to elect up to three additional targets upon payment of additional fees.
  • Cinryze® Phase 2 Trial: ViroPharma initiated a Phase 2b study to evaluate the safety and efficacy of subcutaneous (SC) administration of Cinryze (C1 esterase inhibitor [human]) in adolescents and adults with hereditary angioedema (HAE) for prevention of HAE attacks.
  • MabThera® EMA Filing: Roche submitted a line extension application to the European Medicines Agency (EMA) for a subcutaneous (SC) formulation of MabThera (rituxumab). MabThera SC uses Halozyme's Enhanze Technology, which enables the injection of large volumes of a medication under the skin and may result in faster administration times versus intravenously (IV) administered MabThera.
  • MabThera Positive Trials: Announced positive results from Roche's SABRINA and SparkThera studies, which showed that a fixed dose of MabThera can be administered subcutaneously, potentially allowing patients to spend less time in infusion centers receiving their MabThera treatment. Specifically, the studies showed that subcutaneous injection resulted in non-inferior MabThera concentrations in the blood compared with standard IV infusion.
  • Fourth Quarter and Year End 2012 Financial ResultsThe net loss for the fourth quarter of 2012 was $4.4 million, or $0.04 per share, compared with a net loss for the fourth quarter of 2011 of $18.4 million, or $0.18 per share. The net loss for the year ended December 31, 2012 was $53.6 million, or $0.48 per share, compared to a net loss of $19.8 million, or $0.19 per share for the comparable period in 2011.

  • Revenues for the fourth quarter of 2012 were $21.8 million, compared to $2.4 million for the fourth quarter of 2011. Revenues in the fourth quarter of 2012 included license fees revenue from Pfizer of $9.5 million and a milestone payment from Roche of $4 million.
  • Research and development expenses for the fourth quarter of 2012 were $18.6 million, compared with $14.9 million for the fourth quarter of 2011. The increase was due primarily to an increase in manufacturing activities to support potential launches from our collaborators.
  • Selling, general and administrative expenses for the fourth quarter of 2012 were $7.0 million, compared to $5.9 million for the fourth quarter of 2011.
  • Cash and cash equivalents were $99.9 million as of December 31, 2012, which includes net proceeds of $29.7 million from a term loan with Oxford Finance and Silicon Valley Bank for working capital and other near-term growth initiatives, compared with $52.8 million as of December 31, 2011.  Excluding the proceeds from the term loan, net cash used in the fourth quarter of 2012 was approximately $17.4 million.
  • Financial guidance for 2013 was announced on January 7, 2013 and remains unchanged, with an expected net cash burn to be between $45 and $50 million.

    Conference CallHalozyme will webcast its Quarterly Update and Year End Conference Call today at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, Ph.D., Halozyme's President and Chief Executive Officer, will lead the call. During the call, the Company plans to provide further details underlying its fourth quarter and full year end 2012 financial results. To access the webcast, please log on to approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using replay ID number 409638.

    Upcoming Corporate PresentationHalozyme is scheduled to present at the upcoming Barclays Global Healthcare Conference in Miami on March 12, 2013 at 4:15 p.m. ET/1:15 p.m. PT.

    The presentation will be webcast through the "Investors" section of Halozyme's corporate website at, and the recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

    About HalozymeHalozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

    Safe Harbor StatementIn addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the Company's expected net cash burn for 2013, the development and commercialization of products and the potential benefits and attributes of such products) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse event and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

     Halozyme Therapeutics, Inc.Unaudited Condensed Consolidated Statements of OperationsThree Months EndedTwelve Months EndedDecember 31, December 31, 2012201120122011REVENUES:Product sales, net

    $   1,459,735$
    ,836,102Revenues under collaborative agreements

    20,333,8142,062,88639,437,78454,250,334Total revenues

    21,793,5492,411,16642,325,22656,086,436OPERATING EXPENSES:Cost of product sales

    653,88456,1591,094,400257,834Research and development

    18,567,74414,916,20570,044,07357,563,470Selling, general and administrative

    6,979,0345,866,92124,812,19918,104,073Total operating expenses

    26,200,66220,839,28595,950,67275,925,377OPERATING LOSS

    (4,407,113)(18,428,119)(53,625,446)(19,838,941)Interest and other income, net

    1,25712,50473,44469,090NET LOSS

    $ (4,405,856)$ (18,415,615)$ (53,552,002)$ (19,769,851)Basic and diluted net loss per share

    (0.19)Shares used in computing basic and diluted   net loss per share

    112,323,056103,406,407111,077,105102,566,089 Halozyme Therapeutics, Inc.Unaudited Condensed Consolidated Balance SheetsDecember 31,December 31,20122011ASSETSCurrent assets:Cash and cash equivalents

    $   99,901,264$   52,825,527Accounts receivable, net


    2,670,696567,263Prepaid expenses and other assets

    12,752,8888,332,242Total current assets

    131,027,93563,987,497Property and equipment, net

    3,700,4621,771,048Total Assets

    $ 134,728,397$   65,758,545LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable 

    7,556,859Accrued expenses

    7,783,4475,615,574Deferred revenue, current portion

    8,891,0174,129,407Total current liabilities

    18,946,15317,301,840Deferred revenue, net of current portion

    34,954,96636,754,583Long-term debt, net

    29,661,680-Lease financing obligation

    1,450,000-Deferred rent, net of current portion

    861,879802,006Stockholders' equity:Common stock

    112,709103,990Additional paid-in capital

    347,314,658255,817,772Accumulated deficit

    (298,573,648)(245,021,646)Total stockholders' equity

    48,853,71910,900,116Total Liabilities and Stockholders' Equity

    $ 134,728,397$   65,758,545Investor Contact:
    Kurt Gustafson
    Halozyme Therapeutics

    Media Contact:
    Nurha Hindi
    Hill + Knowlton Strategies

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
    2. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    3. Halozyme to Host Third Quarter Financial Results Conference Call
    4. Halozyme Reports Second Quarter 2012 Financial Results
    5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
    6. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
    7. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    8. Halozyme Reports First Quarter 2012 Financial Results
    9. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    10. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
    11. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
    Post Your Comments:
    (Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
    (Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
    (Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
    Breaking Medicine Technology:
    (Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
    (Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
    (Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
    (Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
    (Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
    Breaking Medicine News(10 mins):